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Abstract
This study examines key elements of glutamatergic transmission within sensory ganglia of the rat. We show that the soma
of primary sensory neurons release glutamate when depolarized. Using acute dissociated mixed neuronal/glia cultures of
dorsal root ganglia (DRG) or trigeminal ganglia and a colorimetric assay, we show that when glutamate uptake by satellite
glial cells (SGCs) is inhibited, KCl stimulation leads to simultaneous increase of glutamate in the culture medium. With
calcium imaging we see that the soma of primary sensory neurons and SGCs respond to AMPA, NMDA, kainate and mGluR
agonists, and selective antagonists block this response. Using whole cell patch-clamp technique, inward currents were
recorded from small diameter (,30 mm) DRG neurons from intact DRGs (ex-vivo whole ganglion preparation) in response to
local application of the above glutamate receptor agonists. Following a chronic constriction injury (CCI) of either the inferior
orbital nerve or the sciatic nerve, glutamate expression increases in the trigeminal ganglia and DRG respectively. This
increase occurs in neurons of all diameters and is present in the somata of neurons with injured axons as well as in somata
of neighboring uninjured neurons. These data provides additional evidence that glutamate can be released within the
sensory ganglion, and that the somata of primary sensory neurons as well as SGCs express functional glutamate receptors at
their surface. These findings, together with our previous gene knockdown data, suggest that glutamatergic transmission
within the ganglion could impact nociceptive threshold.
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Introduction
Glutamate is the common excitatory neurotransmitter of the
central and peripheral nervous systems and is found in both
nociceptive as well as non-nociceptive sensory pathways [1,2,3,4].
The ubiquitous distribution of glutamate has made it difficult to
formulate strategies that could target glutamatergic transmission
involved in a specific function such as nociception while leaving
other processes intact. Thus the possibility of targeting glutama-
tergic transmission in the peripheral nervous system has been
suggested given that small diameter primary sensory neurons,
many of which are nociceptive, express glutamate and glutamate
receptors [5,6,7]. Activation of these neurons leads to glutamate
release at their central as well as peripheral terminals [8,9,10], and
nociception [11,12].
The possibility that glutamate is also released within the sensory
ganglion is contentious as there are no synapses on the soma of
primary sensory neurons. Clearly, the cell membranes of primary
sensory neuron somas contain ionotropic (iGluR) and metabotro-
pic (mGluR) receptors [13,14,15,16]. Moreover, the machinery for
production, release, and recycling of glutamate is present in
sensory ganglia including the amidohydrolase enzyme, glutamin-
ase [17,18], vesicular glutamate transporters (VGLUT1, 2 and 3)
[19,20], the glutamate aspartate transporter (GLAST) and
glutamate transporter 1 (GLT1) [21], as well as the recycling
enzyme glutamine synthetase [17,22]. This, and the presence of
glutamate within the soma would allow for local non-synaptic
glutamatergic transmission. We have indirect evidence for non-
synaptic transmission from experiments in the trigeminal ganglion
in which a glutamate-glutamine cycle enzyme or a glutamate
uptake transporter were knocked-down using double stranded
RNA [22,23]. These studies showed that the knockdown was
confined to the local satellite glial cells (SGCs) and that pain
behavior was consistently altered, which can be best explained by
a change in intraganglionic glutamatergic transmission.
The goal of the present study was to determine if glutamate is
released by the soma of primary sensory neurons and if functional
glutamate receptors are present at the surface of the soma of these
neurons. It has generally assumed that glutamate vesicles and
receptor proteins found in the soma of primary sensory neurons
are destined for transport to axon terminals and that functional
glutamate receptors are not inserted onto the somatic membrane.
Evidence from in vitro studies, however, suggests that the soma of
primary sensory neurons can release glutamate [24,25,26] and
express functional NMDA receptors at the surface [27], support-
ing the presence of intraganglionic glutamatergic transmission [1].
There is precedence for non-synaptic release of other neurotrans-
mitters and neuromodulators within sensory ganglia. Examples are
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adenosine triphosphate (ATP), possibly calcitonin gene related
peptide and tumor necrosis factor-alpha [28,29,30]. These
substances may be released by neurons or glia and their action
would occur locally on one or both types of cells.
It is not known whether or not glutamate receptors other than
the NMDA receptors are present at the somatic membrane of
primary sensory neurons or whether glutamate receptors are also
present on SGCs. To further examine these questions we used a
combination of calcium imaging and glutamate measurements on
acute mixed cultures of adult sensory ganglion together with patch
clamp recordings on intact whole sensory ganglia ex-vivo. Our
results reveal that multiple functional glutamate receptors are
present at the somatic surface of both neurons and SGCs in the
ganglion. We confirmed that primary sensory neuron somas could
release glutamate when they are acutely depolarized. An
unexpected finding was that the glutamate immunoreactivity
increases in the soma of primary sensory neurons in sensory
ganglia after chronic constriction nerve injury (CCI).
Methods
Animals
Adult male Sprague-Dawley rats were used. For CCI-surgery
the rats weighed 270–290 grams and for DRG culture 150–200
grams. All animals were housed on a 12-hour light–dark cycle and
given food and water ad libitum.
Ethics
Procedures for the maintenance and use of the experimental
animals conformed to the regulations of UCSF Committees on
Animal Research and were carried out in accordance with the
guidelines of the NIH regulations on animal use and care
(Publication 85-23, Revised 1996). The UCSF Institutional
Animal Care and Use Committee approved the protocols used
in this study.
Surgery
Chronic Constriction Injury (CCI) of the INFRA-orbital
NERVE (ION). The procedure for CCI of the ION has been
described in detail previously [31]. Briefly, rats were anesthetized
with a mixture of 90 mg/kg ketamine (Fort Dodge Animal Health,
Overland Park, KS, USA) and 10 mg/kg xylazine (Akorn Inc.,
Gurnee, IL, USA) and placed in a stereotaxic head holder. Forty
percent oxygen was delivered through a facemask. The skull and
nasal bone were exposed through a 2 cm supra-orbital skin
incision. The superficial muscle was detached from the superior
edge of the orbit. Gentle retraction of the orbital contents exposed
the ION. Two 5-0 chromic gut ligatures were loosely tied 2 mm
apart around the exposed nerve using the operating microscope
and microsurgical techniques. For sham-operated animals, the
ION was exposed but no ligatures were placed. The skin incision
was closed using interrupted 6-0 silk sutures.
Chronic Constriction Injury (CCI) of the Sciatic Nerve
(SN). We followed the procedure as originally described by
Bennett [32]. Surgery was carried out on rats placed under
anesthesia using 2% isoflurane (Solvay, Mendota Height, MN,
USA) and 40% oxygen delivered through a facemask. The middle
third of the left sciatic nerve was exposed through a 1.5 cm
longitudinal skin incision. Four 4-0 chromic gut ligatures (Ethicon,
Somerville, NJ, USA) were loosely tied around the sciatic nerve
using the operating microscope and microsurgical techniques. The
skin was then closed with interrupted 3-0 silk sutures.
Tissue Processing
Histology. Rats were perfused at 4, 7, and 14 days after CCI-
ION and at 7 and 21 days after CCI-SN under pentobarbital
anesthesia (100 mg/kg i.p.). Perfusions were performed transcar-
dially with 400 mL Tyrode’s solution followed by 400 mL of 4%
paraformaldehyde in phosphate buffer at pH 7.4. Both the
ipsilateral and contralateral trigeminal ganglia or lumbar dorsal
root ganglia, along with samples of brain and spinal cord, were
removed and post-fixed in 4% paraformaldehyde for 3–5 hours,
and then cryo-protected with 30% sucrose in PBS (pH=7.4) for at
least 48 hours. Ganglia from different rats were embedded in the
same block and cut together to minimize processing variation for
quantification. Ten microns (10 mm) longitudinal sections of
ganglia were cut with a cryostat.
Immunohistochemistry. Optimal dilutions and incubation
times for all primary and secondary antibodies were determined
prior to use and control sections with the primary antibody
omitted were used to test for antibody specificity. All slides to be
compared for quantification were processed at the same time. The
following primary antibodies were used at the corresponding
dilutions: rabbit anti-glutamate 1:8000 (#1766 Arnel Products
Co., Inc, NY, USA); mouse anti-beta III tubulin, 1:20,000
(#G7121, Promega, Madison, WI, USA); rabbit anti-activating
transcription factor 3 (ATF3), 1:800 (#sc-188, Santa Cruz, Dallas,
TX, USA); rabbit anti-glutamine synthetase 1:25000 (#G2781,
Sigma, St. Louis, MO, USA); mouse anti-glutamine synthetase,
1:1000 (#MAB302, Chemicon/Millipore, Billerica, MA, USA);
rabbit anti-cellubrevin 1:500, (#104103, Synaptic Systems,
Goettingen, Germany); rabbit anti-SNAP25, 1:500 (#111002
Synaptic system, Goettingen, Germany); guinea pig anti-synapto-
brevin-2 1:200 (#104204, Synaptic Systems, Goettingen, Ger-
many); rabbit anti-SCAMP1 1:400 (#121002, Synaptic Systems,
Goettingen, Germany); rabbit anti-NMDA receptor-1 (NR2A)
1:1000 (AB9864, Millipore, Billerica, MA, USA); rabbit anti-
GluR6 (GluK2) 1:5000 (ab124702, Abcam, Cambridge, MA);
rabbit anti-GluR4 (GluA4) 1:500 (#AB1508, Millipore, Billerica,
MA, USA); guinea pig anti-mGluR8 1:2000 (#AB5362, Chemi-
con/Millipore, Billerica, MA, USA). The tissue was incubated in
primary antibodies at room temperature overnight, then washed 3
4 times before being incubated for 30 minutes in a humidified
chamber with species-specific secondary antibodies conjugated to
FITC or CY3 and diluted 1:500. The slides were then washed and
cover-slipped with Vector shield mounting medium plus DAPI.
Slides were analyzed on both a conventional fluorescence
microscope and a confocal microscope.
Behavioral Testing
CCI of ION; von Frey Hair testing. Three von Frey hairs of
increasing stiffness, 2, 10, and 50 g were used. Five or six
consecutive applications were performed at 5 s intervals on
different areas of the vibrissal pad and in the perioral and
perinasal territory. The observer scored the behavioral response of
the rats based on the method of Vos et al. [33] as follows: 0, no
detection; 1, detection and exploration of the von Frey hair
(sniffing, licking); 2, head withdrawal and/or single grabbing
movement; 3, attack (includes biting) and/or escape (includes
burrowing) and/or multiple grabbing movements; and 4, active
asymmetrical grooming (at least three face wash strokes) directed
toward the stimulated facial area. For each hair, the highest score
was recorded and the results are presented as the average of the
scores obtained from the three different hairs. The average value is
presented because the analysis of scores from each hair separately
gave the same results when compared between groups.
Glutamate as a Neuroglial Transmitter in Ganglia
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CCI of the sciatic nerve SN; von Frey Hair
testing. Testing was done with a von Frey hair algometer
[34]. Briefly, individual rats were placed in a Plexiglas enclosure
(30635613.5 cm) equipped with a metal grid floor with openings
of 0.660.6 cm. A hand-held transducer with a 1.0-mm nylon
probe was gently applied through the metal grid to the plantar
aspect of each hindpaw and progressively pushed vertically until a
paw withdrawal occurred or cut-off was reached (100 g). The
applied force was displayed on a meter attached to the transducer
(IITC, Inc., model 1601, www.iitcinc.com).
Cell Culture
Male Sprague-Dawley rats (150–200 grams) were anaesthetized
with pentobarbital (40 mg/kg, i.p.) and lumbar levels of spinal
cord dorsal root ganglia were dissected and placed into DMEM/
10% FBS containing penicillin (100 U/ml) and streptomycin
(100 mg/ml), followed by three-hour incubation at 37uC and 5%
CO2 with 0.125% collagenase B (Roche, Indianapolis, IN, USA),
then 30 minutes additional incubation with 0.25% trypsin (Sigma,
St. Louis, MO, USA). Afterward DNase I (90 mg/mL; Sigma, St.
Louis, MO, USA) and soybean trypsin inhibitor (100 mg/mL;
Sigma, St. Louis, MO, USA) were added, and the cells dispersed
by trituration using a flame-polished salinized (4% dimethyl-
dichlorosilane in toluene) Pasteur pipette. The resulting cell
suspension was centrifuged 1200 rpm (966g, 20uC) through a
cushion of 15% bovine serum albumin (BSA) (Sigma, St. Louis,
MO, USA) in order to eliminate most of the cellular debris. The
cell pellet was re-suspended in DMEM and centrifuged to remove
the BSA. Using a hemocytometer to determine neurons density,
we seeded 5000 neurons per well onto glass 12 mm cover slips pre-
coated with poly-DL-ornithine (500 mg/mL; Sigma, St. Louis,
MO, USA) and laminin (5 mg/mL; Sigma, St. Louis, MO, USA)
in 24-well tissue culture plates at 37uC and 5% CO2. Cells were
fixed after 24 hours for immunocytochemistry staining. For the
Ca2+ imaging experiments, mixed cultures were plated on 35 mm
diameter coverslips in 6-well culture plates and used for
experiments within 24 to 48 hours.
Glutamate Measurement
Glutamate levels in culture were detected using an enzymatic
assay similar to that described by Akagi and colleagues [35]. In the
presence of glutamate, glutamate oxidase reduces NAD+ to
NADH and produces a-ketoglutarate, NH4
+, and H2O2. The
AmplexH UltraRed reagent (Invitrogen, Grand Island, NY, USA)
reacts with H2O2 in the presence of horseradish peroxidase to
produce bright fluorescence with long-wavelength spectra (Ex.
568 nm, Em. 581 nm) [35] that can be measured in a
spectrofluorometer.
DRG mixed cultures described above were seeded in 96 well
plates at a density of 30,000 neurons per well. Due to the high
density of neurons in each well, the culture medium was changed
every 6–8 hours for 3 days. To avoid glia over population, we used
neurobasal and SM2 as the feeding medium to maintain healthy
neurons and prevent overgrowth of the SGC population. Three
different treatments were included in this study. Group 1 had no
KCl stimulation to serve as a control. Group 2 received 100 mM
KCl to activate neurons. Group 3 was pretreated with DL-threo-b-
Benzyloxyaspartic acid (TBOA 100 mM, Tocris, Minneapolis,
MN, USA) for 2 hours, which blocks glutamate uptake, followed
by KCl stimulation. All reaction agents, excluding TBOA, were
diluted in HEPES medium (mM: 129 NaCl, 5 KCl, 2 CaCl2, 1
MgCl2, 30 glucose, 25 HEPES) and pH-adjusted to 7.4 with
NaOH. TBOA was incubated with culture medium for 2 hours in
group 3 cells prior to KCl stimulation.
Procedure: After 72 hours culture, the medium in all three
groups was replaced with fresh incubation media containing
glutamate oxidase (0.05 U/mL; Sigma, St. Louis, MO) and NAD+
(1 mM; Sigma, St. Louis, MO, USA) with or without KCl
(100 mM). Standard solutions of HEPES containing glutamate (0–
80 mM) containing glutamate oxidase and NAD+ were used to
determine a concentration curve. Two minutes later, the
incubation medium was collected from each well and 1 U/ml
horseradish peroxidase (Sigma, St. Louis, MO, USA) and 50 mM
AmplexH UltraRed (Molecular Probes Inc., Eugene, OR, USA)
were added to each sample. Fluorescence intensity was measured
by spectrofluorometry (FlexStation 3, Molecular Devices, LLC,
Sunnyvale, CA, USA). Protein concentrations were measured with
Pierce BCA Protein Assay Kit (Thermo Scientific, Rockford, IL,
USA).
One-way ANOVA was used to determine if there was
significance between groups and Newman-Keuls post hoc test
were carried out. Each column represents the mean 6 S.E.M. of
total 6 wells/condition, two different cultures from two different
animals.
Calcium Imaging
All drugs used in the in vitro experiments, unless indicated
otherwise, were purchased from Tocris (Tocris, Minneapolis, MN,
USA). DRG mixed cultures (obtained as above) were loaded with
1 mM of Ca2+indicator Fura-2AM and 1 mM of Pluronic F-127
(Life Technologies, Carlsbad, CA, USA) and incubated at 37uC
for one hour. After washing off excess dye, cells were allowed to
complete de-esterfication for at least 30 minutes at 37uC. DRG
mixed cultures were then placed in a recording chamber
(POCmini Chamber system, PeCon, Erbach, Germany) and
continuously perfused with normal bath solution (mM: 129 NaCl,
5 KCl, 2 CaCl2, 1 MgCl2, 30 glucose, 25 HEPES) and pH-
adjusted to 7.4 with NaOH [36] using a perfusion system
(AutoMate Scientific, Berkeley, CA, USA). Fluorescence data
were acquired using Piper control software via a CCD camera at 3
frames/second (XR/MEGA-10, Stanford Photonics Inc., Palo
Alto, CA, USA). The level of intracellular Ca2+ ([Ca2+]i) elicited by
stimuli were measured by the ratio of the emission (510 nm) from
Fura-2 excitation at 340 nm and 380 nm. The [Ca2+]i concen-
tration induced by ionomycin at the end of each experiment was
taken as the maximum 340/380 ratio and set as 1.
All drugs to be tested were applied directly using a hand-held
Eppendorf pipette. The chamber contained 1 ml of HEPES to
which the drug was added diluted in 500 ml of HEPES to giving
the target concentration indicated in Table 1. Prior to drug
application, 500 ml of HEPES buffer was infused to control for
mechanical calcium transients. The target concentrations in the
chamber for all agonists were: Glutamate (200 mM), AMPA
(50 mM), NMDA (100 mM), DHPG (mGluR group I agonist,
100 mM), and kainic acid (KA) (30 mM). The concentrations of the
respective antagonists were: CNQX (100 mM), APV (100 mM),
AP3 (1 mM) and UBP310 (0.5 mM). Cells were recorded for
baseline HEPES medium (prior to drug application) for at least 5
minutes, then the agonist applied and they were recorded for 10
minutes. After washing for 10 minutes, the antagonists CNQX,
APV, AP3, UBP310 were then individually applied for 10 minutes
prior to a second application of the appropriate agonist. Next,
following a 10-minute wash, KCl (50 mM) was perfused for 2
minutes to identify the neuronal population. Lastly, ionomycin
(20 mM) was added to the medium to verify the viability of cells.
Cells that did not respond to ionomycin were excluded from the
experiment.
Glutamate as a Neuroglial Transmitter in Ganglia
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Baseline value were acquired by averaging the 340/380 ratio 10
seconds prior to drug application and compared to the peak value
which is 10 seconds of the maximum peaks response following
drug application. The equation to get the % increase response
from baseline is: (peak value – baseline value)/baseline value x100.
The ratio of 340/380 responses to drugs between neurons and glia
was compared before and after glutamate was added using paired
Student’s t- test. The same test was also used to determine the
difference between agonist effect alone and agonist effect in the
presence of the antagonist for the same cell.
Intact Dorsal Root Ganglion (ex-vivo) Preparation and
Whole Cell Patch Clamp Recording
For collecting intact DRGs, rats were first deeply anaesthetized
with pentobarbital (40 mg/kg, i.p.). The L4 and L5 DRG were
removed and placed into artificial cerebral spinal fluid (aCSF).
The aCSF contained (in mM): 124 NaCl, 2.5 KCl, 1.2 NaH2PO4,
1.0 MgCl2, 2.0 CaCl2, 25 NaHCO3 and 10 glucose in sterile
preservative free deionized water. The connective tissue surround-
ing the DRG was carefully removed under high magnification,
and then the ganglia were incubated with a mixture of 0.4 mg/mL
trypsin and 1.0 mg/mL type-A collagenase (Sigma, St. Louis, MO
USA) for 40 minutes at 37uC to remove the remaining
epineurium. The ganglia were then incubated in aCSF bubbled
with 95% O2 and 5% CO2 at room temperature for at least
1 hour before being transferred to the recording chamber.
Neurons were visualized with a 40X water-immersion objective
using a microscope (FN-600, Nikon, Japan) equipped with infrared
differential interference contrast optics. The image was detected
with an infrared-sensitive CCD (IR-1000, Dage MTI, USA) and
displayed on a monochrome video monitor. Whole-cell current
recordings were acquired with an Axon200B amplifier (Molecular
Devices, Sunnyvale, CA, USA). Patch pipettes were pulled from
borosilicate glass capillaries (BF150-86-10, Sutter Instruments) on
a puller (P97, Sutter Instruments, Novato, CA, USA). The
resistance of the pipette was 4–5 MV when filled with the pipette
solution which contained (in mM): 140 KCl, 2 MgCl2, 10 HEPES,
2 Mg-ATP, 0.5 Na2GTP, pH=7.4. Osmolality was adjusted to
290–300 mOsm.
After a giga seal was established, the membrane was broken and
neurons with a resting membrane potential below 250 mV were
selected for further study. The access resistance was 10–20 MV
and continuously monitored and data were discarded if the access
resistance changed more than 15% during an experiment. For all
agonists induced currents, the neurons were clamped at 270 mV
except for NMDA neurons, which were clamped at 240 mV.
Data were acquired with a Digidata 1440 A acquisition system
(Molecular Devices) and pCLAMP 10.2 software (Molecular
Devices). Signals were low-pass filtered at 5 kHz, sampled at
10 kHz, and analyzed offline.
Drug application. All drugs used in the ex-vivo experiments
were purchased from Tocris (Tocris, Minneapolis, MN, USA).
Drugs were dissolved in ultra-pure deionized water as stock
solutions and refrigerated for later use. All stock solutions were
diluted with aCSF before use.
Table 1 shows the target concentration of glutamate (1 mM),
AMPA (100 mM), NMDA (100 mM), KA (100 mM) and DHPG
(1 mM) were applied with focal pressure ejection via a puffer
pipette controlled by a Picospitzer II (200 ms puff at 1–2 psi;
General Valve Inc) to activate the receptors. The corresponding
receptor antagonists (Table 1), APV (50 mM)+CNQX (10 mM ),
APV (50 mM), CNQX (10 mM), AP3 (60 mM) and UBP310
(0.5 mM) were bath-applied for at least 5 minutes to test the
blocking effect. In order to test the blocking effect of receptor
antagonists, the responses induced by each agonist before
antagonist application were set as 100%, and the currents after
antagonist application were expressed as the percentage of
previous response. All results were presented as the mean 6
SEM. The paired Student’s t- test was used to compare agonist
induced inward currents and antagonists induced inward currents.
Tau of decay is calculated as the time from 100% of peak value to
50% of peak value.
Quantification of Glutamate Expression
Quantification was done on images taken at the same
magnification from glass slides that contained sections of the
sensory ganglia ipsilateral and contralateral to the CCI. All images
were acquired using the same microscope and camera setting. The
Image J (version 1.44, rsbweb.NIH.gov/IJ/) software was used to
determine a threshold (see Results) for which glutamate staining
was considered to be above background. The same threshold was
then used for all ganglia on the same slide that included both
ipsilateral and contralateral ganglia from all time points. For each
slide a new threshold was set in order to normalize for variation in
tissue processing. The total number of pixels was determined for
each section to quantify the glutamate staining (i.e. above
threshold). For measuring changes in glutamate immunolabeling
related to cell size, the area was calculated from the measured
diameter of those cells above background in which the nucleus was
visible.
For quantification on the trigeminal ganglia we used 3 sections
per rat (2 sham and 3 CCI-ION animals per group). For DRG
glutamate expression quantification we used 3 sections at each
spinal level from 3 animals at 7 and 21 days post CCI. Cells were
characterized as small if their cross-sectional surface area was less
than 800 mm2, medium if the area was 800–1800 mm2, and large if
the area greater than 1800 mm2 [37]. Percent changes in
Table 1. Agonists and antagonists used in calcium image and patch clamp experiments.
Agonist Calcium Image Ex-vivo Patch Clamp Antagonist Calcium Image Ex-vivo Patch Clamp
Glutamate 200 mM 1 mM APV+CNQX - 50 mM+10 mM
NMDA 100 mM 100 mM APV 100 mM 50 mM
AMPA 50 mM 100 mM CNQX 100 mM 10 mM
KA 30 mM 100 mM UBP310 0.5 mM 0.5 mM
DHPG 100 mM 1 mM AP3 1 mM 60 mM
KA (kainic acid, kainate receptor agonist), DHPG (mGluR1/5 agonist), APV (NMDA antagonist), CNQX (AMPA/Kainate receptor antagonist), AP3 (mGluR1/5 antagonist),
UBP310 (Kainate receptor specific antagonist).
doi:10.1371/journal.pone.0068312.t001
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immunoreactive pixel area from paired ipsi/contralateral sides for
each sensory ganglion were compared using individual Student’s t-
test for each time point (4, 7 or 14 days).
Results
Glutamate is Released from Mixed DRG Cell Culture
In this experiment, we asked two questions: whether neuronal
stimulation can induce glutamate release from somas and whether
blocking glutamate uptake will increase the extracellular concen-
tration of glutamate. We used a colorimetric assay to detect
glutamate released into the medium of a mixed neuronal/SGC
culture. Data were collected from six wells per treatment and
cultures from 3 different animals. Following 2 minutes of
stimulation by addition of 100 mM KCl, the extracellular
glutamate concentration increased (Figure 1; 18.9 nmol/mg
65.2 vs. 3.1 nmol/mg 60.6) but was not significantly different
from control. Because glial cells in the mixed culture rapidly take
up extracellular glutamate, we then pretreated cultures with
TBOA in order to block glial glutamate uptake. Addition of
100 mM KCl for 2 minutes to these cultures resulted in a
significant elevation of extracellular glutamate (83.4 nmol/mg
623.4) compared to buffer control (3.1 nmol/mg 60.6) or KCl
stimulation without TBOA (18.9 nmol/mg 65.2) (P,0.001)
conditions.
Neurons and SGCs are Activated by Glutamate
To examine whether neurons and glial cells in the DRG express
functional glutamate receptors, we measured glutamate evoked
cytoplasmic Ca2+ responses in 24 hr dissociated mixed (neurons
and SGCs) DRG cultures (Figure 2). Neurons were identified by
their diameter (large .30 mm, small ,30 mm) and by their
immediate Ca2+ influx in response to KCl (50 mM) application.
SGCs were recognized by characteristic close association with
neurons and by their much smaller diameter (i.e. ,10 mm).
Figure 3 shows representative traces of neurons (A) and SGCs (B)
following addition of glutamate agonists to the culture. Glutamate
(200 mM) applied to 1 day mixed primary dorsal root ganglion
culture induced an increase in cytosolic Ca2+ of both large and
small neurons 12.761.8 (Figure 3A, C) and SGCs 7.8161
(Figure 3B, C). Fifty-one out 56 (91%) neurons and 34 out of 40
(85%) SGCs responded to glutamate application. This effect was
not due to the mechanical effect of applying the drug as the 340/
380 ratio did not change after direct application of HEPES buffer
alone (data not shown).
DRG Perikarya and SGCs have Functional Ionotropic and
Group I Metabotropic Receptors
We examined which subtypes of glutamate receptors were
responsible for the increase in cytosolic Ca2+. Ionotropic and
group I metabotropic receptor agonists AMPA, NMDA, KA, and
DHPG were used to stimulate cells. The selective antagonists
CNQX, APV, AP3 and UBP310 were used to block the effect of
each agonist (Figures 4 and 5). As shown in Figure 4, all four
agonists caused an immediate Ca2+ influx, which lasted through
the entire recording period (10 minutes) in both SGCs (Figure 4
A–D) and neurons (Figure 4 E–H). To confirm the selectivity of
the agonists, 5 minutes incubation with the appropriate antagonist
was able to block the effect of a second application of agonists in
SGCs (Figure 4 A1–D1) and neurons (Figure 4 E1–H1). The
summary data are shown in both Figure 5 and Table 2. Similar
results were found in both neuron and SGC populations.
To confirm that the reduction in Ca2+ influx following
antagonist application was not the result of receptor sensitization
[38], we tested whether glutamate and selective glutamate agonists
can induce Ca2+ influx after repeated application with washes
between applications. We found that all agonists were capable of
increasing the 340/380 ratio after washing 2 to 3 times (data not
shown). From this we conclude, the reducing Ca2+ influx ratio
after pretreatment of antagonist was not due to desensitizing of the
receptors.
Activation of DRG Neuronal Perikaryal Glutamate
Receptors causes Inward Currents
Patch clamp recordings were made from 122 neurons of which
45 (36.9%) showed responses with inward currents to application
of 1 mM glutamate. Pooled data from these neurons show the
amplitude of the current was 234.3639.9 pA (Table 3). The
currents induced by glutamate were blocked by bath application of
50 mM APV and 10 mM CNQX (Figure 6A 84.2% 63.4
amplitude decrease from agonist alone, N= 8, P,0.001) indicat-
ing that the glutamate response was mediated at least by AMPA
and NMDA receptors. To further investigate the receptors
underlying the glutamate response, neurons were tested with
selective agonists and antagonists (Figure 6; Table 3). In the
presence of the ionotropic antagonists, CNQX, APV, AP3 or
UBP310 currents induced by glutamate, ionotropic agonists
AMPA, NMDA, KA or metabotropic agonist DHPG, respective-
ly, were significantly reduced by ,80% (Table 4). These results
showed that ionotropic (NMDA, AMPA, KA) and metabotropic
(mGluR1/5) receptors were functionally expressed on the
perikarya of DRG neurons.
Glutamate Immunosignal is Increased after CCI of the
Sciatic Nerve
Seven days following CCI of the sciatic nerve, glutamate
immunosignal was measured in neurons of spinal ganglia at the L3
to L6 levels ipsilateral to the CCI and compared to the
contralateral side (Figure 7A–E). The L4 and L5 ganglia that
provides the majority of axons to the sciatic nerve showed
increases of 446% (6108%) and 202% (660%,) while glutamate
Figure 1. Glutamate assay of dissociated DRG cultures.
Colorimetric assay shows that following KCl (100 mM) application to
the culture medium there was an increase in glutamate release which
did not reach significance compared to control (no stimulus/HEPES
only). Following pretreatment with a glutamate transporter blocker
(TBOA 100 mM), KCl stimulation resulted in a significant increase in
extracellular glutamate concentration. Each column represents the
mean of 3 wells per condition. Each column represents the mean 6
S.E.M. One-way ANOVA **, P,0.01.
doi:10.1371/journal.pone.0068312.g001
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Figure 2. Confocal and calcium influx images of a 24-hour DRG primary mixed culture. A–C confocal image showing SGCs (red: glutamine
synthetase an SGC marker, open arrow), neuron (green: b-tubulin, solid arrow) and nucleus (blue: DAPI). D–F representative pictures from a 24-hour
culture used for calcium imaging. D and E (high magnification) were taken before the start of calcium imaging. F, fluorescent image following 200 mM
glutamate application showing an increase in the 340/380 ratio indicated by an increase in signal intensity in the neuron (N), and two SGCs (yellow
arrows) compared to the SGC which did not respond (white arrow). C, D, E, F, scale bar: 10 mm.
doi:10.1371/journal.pone.0068312.g002
Figure 3. Representative calcium imaging fluorescent traces of a neuron and SGC. A, B, following application of 200 mM glutamate both
neurons and SGCs showed an increased fluorescent ratio during the 10 minutes of recording. A1, B1 after washing with HEPES buffer, KCl (50 mM)
was given to identify neurons in the recorded field. Ionomycin (20 mM) was added to test for cell viability at the end of the experiment. Lines show
the duration of application for experimental agent. Scale bar = 5 minutes. C, average relative glutamate induced maximum change of 340/380
fluorescence ratio from pre-drug (baseline, normalized at 0) condition. Paired Student’s t- tests were used to compare pre-drug and post-drug
conditions. Mean 6 S.E.M. ***P,0.001.
doi:10.1371/journal.pone.0068312.g003
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levels in the L3 and L6 were not significantly different from the
non-ligated side (L3, 77% 631%; L6, 45% 623%). Twenty-one
days after CCI, glutamate expression in all ganglia (L3–L6) was
not significantly different compared to the contralateral side
(Figure 7 F). Comparison of glutamate immuno-expression on the
contralateral side between days 7 and 21 showed no significant
difference (P.0.05) indicating that the reduction in the ipsilateral
expression at 21 days following ligation was not due to an
increased expression of the contralateral side. Animals were also
monitored behaviorally every other day using von Frey hairs. All
animals exhibited a decreased pain threshold on the side of the
CCI of the sciatic nerve (left side), which was significant at 7 and
21 days (Day 0, left = 72.44 g, 63.99, right 71.63 g, 65.19 g,
p = ns; Day 7, left = 31.08 g, 62.92 g right 70.84 g, 65.03 g,
p,0.001; Day 21, left = 45.85 g, 64.59 g, right 86.52 g, 61.08 g
p=,0.001).
Glutamate Expression is Increased in Trigeminal Ganglion
after CCI of the ION
To determine whether an increase in somatic glutamate also
occurred in the trigeminal ganglia, we performed glutamate
immunocytochemistry at days 4, 7 and 14 post-CCI of the ION
(Figure 8). Rats were also tested behaviorally every other day using
von Frey hairs. Decreased pain thresholds were observed on the
side of the nerve injury (left side) throughout the study period (Pain
score. Day 0, left = 2.060.5, right = 2.060.5, p= ns; Day 7,
Figure 4. Representative calcium imaging traces of SGCs and neurons following application of glutamate agonists and antagonists.
Following direct application of A: AMPA (50 mM), B: NMDA (100 mM), C: DHPG (100 mM) and D: KA (30 mM) both neurons and SGCs responded to all
three agonists. Following a HEPES buffer wash the same cells were then given the appropriate selective antagonist: A1, E1: CNQX (100 mM); B1, F1: APV
(100 mM); C1, G1: AP3 (1 mM) and D1, H1: UBP310 (0.5 mM) for 5 minutes prior to second application of agonist. In the presence of its antagonist, the
effect of each agonist was blocked (A1–D1 SGCs; E1–H1 neurons). A2–H2, ten minutes after HEPES buffer wash, KCl (50 mM) was given to identify
neurons in the recorded field and ionomycin (20 mM) was added to test cell viability at the end of the experiment. Lines show the duration of
application. Scale bar = 5 minutes.
doi:10.1371/journal.pone.0068312.g004
Figure 5. Summary data of calcium imaging experiment on
glutamate receptor activation. Effects of each agonist were
significantly blocked in the presence of their respective antagonists
(A, SGCs; B, neurons) in calcium imaging experiments. Pre-treatment of
the selective appropriate antagonist, resulted in a reduction in
activation by the agonist of both neurons and SGCs. Cell numbers
used in this summary bar graph (neuron/SGC): AMPA (25/35), NMDA
(12/9), DHPG (20/5) and KA (11/22). Each agonist used 3–4 cultures from
2–3 animals. Each column represents the mean 6 S.E.M. ***, P,0.001;
**P,0.01.
doi:10.1371/journal.pone.0068312.g005
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left = 3.5, 60.5, right = 2.160.2, p = 0.42; Day 14, left = 3.860.4,
right = 2.36=0.3, p= 0.002). Increased glutamate expression was
observed in the ipsilateral compared to the contralateral ganglia at
all three time points post CCI (Figure 8 I, 4 days, 180655%;
7 days, 260653%; 14 days, 5066186%). In animals with sham
surgery there was no difference in glutamate expression between
left and right trigeminal ganglia (Figure 8 I). The neurons showing
increased glutamate expression were not confined to a specific cell
size but occurred through the entire population (Figure 8 J). To
show the increased in glutamate occurred in the territory of the
injured ION we double labeled for both glutamate and ATF3
(Figure 9). ATF3 is a marker of neuronal injury [39]. While the
increase in glutamate was in the portion of the trigeminal ganglia
that harbors the somas of neurons with projections in the ION, not
all neurons with increased glutamate expression had ATF3
immunopositive nuclei (Figure 9).
Discussion
Glutamate is Released into the Extracellular Space within
the Sensory Ganglion
It is well established that glutamate is released from both the
central and peripheral axonal endings of primary sensory neurons
[11,12,40] but the possibility that glutamate is also released from
the cell body (soma), although not a new concept, is not widely
recognized. More than two decades ago, Larson’s group reported
that cultured whole ganglia released glutamate in response to KCl
or capsaicin [26] stimulation. Our results, and those of others
[24,25], confirm that glutamate is released from dissociated DRGs
and trigeminal ganglia following KCl stimulation. When cortical
[41] or DRG primary cultures (present study) were pretreated with
TBOA, an inhibitor of glutamate uptake with a higher affinity for
glial transporters, the amount of extracellular glutamate following
KCl treatment increased markedly. This is evidence for the key
role played by SGCs in regulating glutamatergic transmission
within the ganglion [17] given that most of glutamate reuptake
occurs through glial transporters [21,42,43]. This observation
complements a previous in-vivo study in the trigeminal ganglion
when we silenced the expression of GLAST, one of the two glial
glutamate transporters. For the duration of the silencing (3–4 days)
all rats presented a neuropathic-like pain behavior in the
innervation territory of the trigeminal nerve [22]. We postulated
that the behavioral changes were due to increased extracellular
glutamate resulting from reduced glial uptake, a situation
mimicked by the addition of TBOA to mixed cultures in the
present study.
Although there are no synapses in the ganglion, or at the
peripheral terminals where glutamate is known to be released [44],
a vesicular mode of release is not excluded [44,45]. Some
components of the vesicular docking mechanism are seen at the
level of the somatic membrane within the ganglion (Figure S1).
Alternatively, channels and transporters through which non-
vesicular release of glutamate occurs are also present, including the
cystine-glutamate antiporter [46], gap junctions (connexin 43)
[23], the P2X7 channel [28,47], or reverse transport through
GLAST or GLT1 [21,43]. Although we did not see glutamate
immuno-staining in SGCs it is possible that this due to the limited
sensitivity of immunocytochemistry. Studies showing that astro-
cytes are able to synthesize and release glutamate [48,49,50]
suggest that this might also occur for SGCs, yet it remains to be
shown.
Glutamate Receptors in Primary Sensory Neurons
The weight of evidence supports the idea that glutamate is
released from neuronal cell bodies within sensory ganglia but this
leaves open the question of whether such release has any
functional consequences. In other words, are there functional
glutamate receptors on the perikarya within the ganglia?
Anatomically, NMDA, AMPA, kainate and metabotropic recep-
tors have been reported in primary sensory neurons [13,14,15].
NMDA receptors are expressed in 40 to 60% of primary sensory
neurons most of which are nociceptive (i.e. small diameter) while
AMPA is expressed in about 34% of primary sensory neurons
[15,16]. Kainate receptors are the only glutamate receptor found
exclusively in small diameter primary sensory neurons [13]
suggesting a closer association between this receptor and
nociception in the periphery. Metabotropic GluR 1/5 receptor
are also expressed mainly by small diameter neurons (30 microns)
but their distribution is limited (less than 7% of DRG neurons)
[14].
The immunocytochemical identification of receptor proteins in
the soma does not necessarily indicate these are functional
receptors as they could represent subunits of glutamate receptors
that are destined to be exported to the central or peripheral axon
terminals where they are inserted into the membrane. Evidence
for the presence of functional receptors comes from the present
study and previous pharmacological and electrophysiological
studies showing that application of glutamate receptor agonists
depolarize cultured DRG neurons and activate Ca2+-dependent
currents. There are some discrepancies in the results from previous
studies when it comes to which receptor is involved at the soma.
Table 2. Neurons and SGCs responding to glutamate or selective agonists with or without specific antagonists using calcium
imaging.
Agonist vs. Antagonist+Agonist
Responding
Neurons
#/total N (%) D 340/380 ratio neurons
Responding SGCs
#/total N (%) D 340/380 ratio SGCs
Glutamate 51/56 (91) 12.761.8*** 34/40 (85) 7.8161***
AMPA vs. CNQX+AMPA 25/29 (86) 9.862.1 vs. 1.060.8*** 35/37 (95) 11.961.7 vs. 1.660.8***
NMDA vs. APV+NMDA 12/23 (52) 4.860.9 vs. 1.360.9** 7/14 (50) 11.163.7 vs. 0.960.9**
KA vs. UBP310+ KA 11/13 (85) 23.868.6 vs. 0.361.4** 22/24 (92) 24.863.1 vs. 3.661.2**
DHPG vs. AP3+ DHPG 20/21 (95) 9.462.0 vs. 1.461.1*** 5/6 (83) 12.261.8 vs. 2.162.3**
Mean 6 S.E.M.
**P,0.01;
***P,0.001.
doi:10.1371/journal.pone.0068312.t002
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Figure 6. Whole cell patch recordings of small neurons from ex-vivo dorsal root ganglia. A–E, puff application of glutamate or the receptor
selective agonists induced inward currents which were blocked (right trace) by bath application of the appropriate selective antagonist(s). A1–E1, bar
graphs showing the reduction in standardized amplitude of the receptor induced currents in presence of the appropriate antagonist. See Table 1 for
drug concentrations. The bars above all the traces indicate agonist application time (200 ms). The decay time for AMPA induced current is:
520.0670.4 ms; NMDA: 461.9639.7 ms; Glutamate: 537.0650.8 ms; KA: 512.46482.4 ms; DHPG: 90.1625.8 ms. All data are expressed as mean 6
SEM. ***P,0.001.
doi:10.1371/journal.pone.0068312.g006
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Lovinger and Weight concluded that NMDA but not kainate
receptors were active on the perikarya of a large proportion
primary sensory neurons [51] while Huettner, using whole-cell
voltage clamp, found that most neurons exhibit strong responses to
kainate receptor agonists, but less response to AMPA and NMDA
agonists [52]. In contrast, Agrawal and Evans [53] recorded strong
depolarization to KA and to a lesser degree to AMPA in dorsal
root fibers, but found little or no response when KA or other
excitatory amino-acids were applied directly to the ganglia. For
metabotropic receptors, it has been shown that the mGluR5 (but
not mGluR1) receptor subtype underlies the glutamate-mediated
oscillatory increases in Ca2+ at the soma [54,55] while group II/III
mGluRs appear to have an inhibitory effect [56].
Our data expands previous studies by showing that all three
types ionotropic receptors as well as group 1/5 mGluR are present
on the perikarya of primary sensory neurons and all respond to the
appropriate selective agonists with inward currents. Of particular
note is that our results were obtained using two different methods
on different tissue preparations, Ca2+ imaging studies on
dissociated ganglia and patch clamp studies on intact, ex-vivo,
whole ganglia. In the latter case because the neuron/SGC
relationship is preserved and the neurons retain their central
and peripheral axons, it is unlikely that the glutamate receptor
response can be artifactually induced by the dissociation or culture
conditions.
Our Ca2+ imaging studies have provided additional data not
available from the ex-vivo experiments. Calcium imaging shows
that AMPA [57], NMDA, kainate, and mGlu [14] receptors on
SGCs (Figure S2), respond to the appropriate selective agonists,
meaning that they are functional. The mGluR response confirms
an earlier observation in the nodose ganglion by Shoji and
colleagues [58] who showed an increase in intracellular Ca2+ in
both neurons and surrounding SGCs in response to glutamate or
the mGluR agonist (t-ACPD). This latter result indicates that
SGCs in autonomic ganglia also express functional glutamate
receptors.
The kinetics of Ca++ influx were similar when either AMPA,
NMDA or DHPG was applied although the kinetics of activation
would be expected to be different for the different receptors. The
similarity in responses in our experiments can be explained by the
fact we are sampling at 300 milliseconds/frame, so we are unable
to differentiate any event faster than 300 milliseconds NMDA and
AMPA channels open in the 1–10 milliseconds range while
metabotropic receptors activate in the 50–100 milliseconds range
and thus are outside our temporal resolution. We also do not know
the origin of AMPA-mediated calcium entry; Fura 2A (calcium
indicator dye) only indicates the amount of calcium change inside
the cell. The calcium responses we observed could result from the
calcium permeable AMPA or NMDA receptors and/or activation
of voltage gated calcium channels all of which open and close
within millisecond range and cannot be differentiated with our
calcium imaging protocol. Finally it should be noted that the
application method is such that the drugs takes several seconds to
dissipate, so the recording is from a large number of receptors
being activated over several seconds and therefore it is not possible
to determine individual channel kinetics.
The importance of functional glutamate receptors on primary
sensory cell bodies is fairly straightforward. It means that
extracellular glutamate in the ganglia can change the membrane
potential of the ganglion neurons. The consequences in terms of
changes in sensory processing will depend on the magnitude of the
membrane threshold changes, whether ionotropic or metabotropic
channels are involved and differences between physiological
classes of neurons. This adds to the growing recognition of
complex chemical messenger interactions between neurons and
SGCs within sensory ganglia. The most established is through the
release of ATP that activates local purinergic receptors
[29,59,60,61]. In response to stimulation, SGCs have been shown
to release a variety of cytokines [29,60,62].
Glutamate Increases in the Cell Body of Primary Sensory
Neurons after Peripheral Nerve Injury
The number of glutamatergic neurons in primary sensory
ganglia has been previously reported as being between 30 and
70% [6,7,44,63,64]. Quantitation using immunocytochemistry has
to be treated with caution as technical issue such as antibody
sensitivity can bias the results and in fact several of the above
authors have noted variable results depending on the method used
[64] or use of colchicine [7]. The latter study [7] observed a large
Table 3. Neurons responding to glutamate or selective
receptor agonists in ex-vivo patch-clamp experiments.
Agonist Total (N)
Cell responding
(%)
Mean of inward current
(pA)
Glutamate 122 37 234.3639.9
AMPA 38 29 275.8645.1
NMDA 55 33 554.0694.8
KA 21 81 128.2632.0
DHPG 50 24 89.9638.2
Mean 6 S.E.M.
doi:10.1371/journal.pone.0068312.t003
Table 4. Neurons responding to selective antagonist following agonist treatment.
Antagonist
(Figures 6A1–6E1) Total (N) Cell responding (%)
Mean of inward currents induced by
second application of agonist in the
presence of antagonist (pA)
Mean of inward currents reduction from
first application of agonist (%)
APV+CNQX 8 100 37.066.2 84.263.4***
CNQX 7 100 34.468.5 79.764.0***
APV 7 100 89.0615.1 83.063.9***
UBP310 3 100 5.161.3 96.961.0***
AP3 7 100 15.163.2 81.761.7***
Mean 6 S.E.M.
***P,0.001.
doi:10.1371/journal.pone.0068312.t004
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increase in the number of glutamate positive perikarya after
colchicine treatment which suggests that negative results might
result from insensitivity of some immunocytochemical methods. It
can be seen in our Figures 7 and 8 that all neurons in the
trigeminal ganglia and DRG appear to have some amount of
staining and determining what is background is somewhat
arbitrary. However, it should be noted that glutamate has non-
neurotransmitter functions in cell metabolism [65,66] therefore
low levels of immunoreactivity need not necessarily be artefactual.
Because the number of immunopositive cells counted depends on
where the cut-off for background staining is set we did not try and
estimate the total number of glutamate immunopositive neurons
but rather we determined the increase in glutamate expression
following injury. We also used a relatively high threshold that was
the same for both the injured and non-injured ganglia (they were
processed side-by-side on the same slide) and reported the change
in immunolabeling of the injured side compared to the uninjured
side.
A significant increase in glutamate immuno-staining was seen,
as early as 4 days post-CCI in the trigeminal ganglion and at
7 days in the L4 and L5 DRGs. This increase lasted until day 14
post-CCI for both the trigeminal and lumbar sensory ganglia. The
rise in glutamate occurred in neurons that were injured by the
CCI or were located in the region of the ganglion containing
injured neurons. This is demonstrated both by the double label
studies with glutamate and ATF3 and also by the finding that the
increase in glutamate was localized to the V2 division of the
trigeminal ganglion where axons in the ION arise and throughout
the L4 and L5 spinal DRGs ipsilateral to the sciatic nerve ligation.
Approximately half the neurons of L4/L5 DRGs project axon into
the sciatic nerve [67] in contrast to only 0.4% the L6 and 1.2% of
the L3 DRG neurons [68]. Accordingly, no significant increase in
glutamate was seen in the L3 and L6 ganglia. The increase in
glutamate was seen in neurons of all diameters and is consistent
with the fact that all sizes of axon are injured in the CCI model
[69].
While there are no previous reports of glutamate increasing in
the sensory ganglion after peripheral nerve injury, Westlund et al
[70] reported an increase in the number of glutamate immuno-
positive in peripheral fibers from 25% to over 60% following
induction of arthritis; the ganglia was not examined. The
glutamate increase we report in injured neurons as indicated by
ATF3 [39] expression may be due to increased activity or from
decreased axonal transport. Why glutamate increases in non-
injured (i.e. ATF3 immunonegative) neurons is not clear. It could
be due to a paracrine effect via factors such as neurosteroids [71],
chemokines [72], serotonin [73], or glial cell line-derived
neurotrophic factor [59] released in the ganglion by injured
neurons. The increase in glutamate is likely to be associated with
increased release given that after nerve lesion the vesicular
transporter VGLUT2 also increases in small diameter ganglion
neurons [74], voltage activated Ca2+ channels are upregulated,
Ca2+ dependent of glutamate release increases, and reuptake
decreases [75,76,77,78,79]. It is unclear what proportion of the
glutamate seen in the soma of primary sensory neurons (baseline
or after nerve injury) is released in the ganglion and what
proportion from peripheral or central terminals.
While the importance of glutamate as a neurotransmitter in the
CNS and in primary afferent terminals is well documented
[80,81,82], the role of glutamate within the ganglion is not
established. The present data showing that CCI is accompanied by
an increase in glutamate in the soma of sensory ganglion neurons
Figure 7. Representative images from an L4 DRG immunostained for glutamate following CCI of the sciatic nerve. Increased
glutamate immunolabeling is seen in the DRG ipsilateral to the sciatic CCI (A standard, C thresholded image) compared to the contralateral side (B
standard, and D thresholded image). E, F shows the % difference in glutamate immuno-expression between the ipsi and contralateral L3 - L6 DRGs at
7 (E) and 21 (F) day post-CCI-SN animals. Scale bar = 50 mm. Data expressed as mean 6 SEM. **, P,0.01; ***P,0.001 ipsilateral vs. contralateral.
doi:10.1371/journal.pone.0068312.g007
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Figure 8. Representative images from a trigeminal ganglion immunostained for glutamate following CCI of the ION. Increased
glutamate immunolabeling is seen in the trigeminal ganglion ipsilateral to the CCI (A, standard, C, thresholded image) compared to the contralateral
side (B, standard, D, thresholded image). I, shows the % difference in glutamate immuno-expression between the ipsi and contralateral trigeminal
ganglion for sham, 4, 7 and 14 days post CCI. Ganglia from sham-operated rats (E, standard, G, thresholded image) showed no difference compared
to contralateral ganglia (F, standard, H, thresholded image). J, white bars show total glutamate immunopositive cells sorted by size from 9 sections of
three 14-day CCI-ION trigeminal ganglion and the black bars show the number glutamate positive cells above threshold. Scale bar = 50 mm *, P,0.05;
**, P,0.01; ***, P,0.001.
doi:10.1371/journal.pone.0068312.g008
Figure 9. Relation between injured neurons and change in glutamate expression. Seven days following CCI of the inferior orbital nerve
many neurons show increased levels of glutamate immunosignal (A, arrows and see Figure 8). Not all these cells are double labeled for ATF3 (B,
arrows) a marker of neuronal injury. The neurons indicated with arrowheads are also above threshold but not ATF3 immuno positive. This is not due
to the nucleus being out of the plane of section as DAPI staining (C, arrowheads) shows nuclei are present. Scale bar = 30 mm.
doi:10.1371/journal.pone.0068312.g009
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suggesting that glutamate in the ganglion may be the key in the
initial expression of neuropathic pain and triggering the events in
the CNS that leads to chronic pain.
Even with the evidence that glutamate can act locally in the
ganglion to activate receptors, there is the question of whether
intraganglionic glutamate activity has any relevant behavioral
effects. We have previously shown that knockdown of components
of the glutamate uptake and recycling mechanism in SGCs results
in quantifiable spontaneous pain behavior, ipsilateral allodynia
and ipsilateral hyperalgesia [22,23]. We hypothesized that
interrupting glutamate uptake and recycling by SGCs resulted in
an increase in extracellular glutamate and activation of glutamate
receptors, which may in turn change the excitability of the
ganglion neurons. More experiments will have to be done to
address this question. This model is analogous to pharmacolog-
ically blocking glutamate uptake in the spinal cord, which results in
nociceptive responses [83,84].
If the nociceptive actions of glutamate release within the
ganglion is confirmed, then altering glutamatergic transmission
within the ganglion might be an avenue for pain therapy. The
rationale of targeting glutamate in the early stages of nerve injury
is supported by data showing that glutamate uptake is less efficient
after nerve injury [85,86,87] and restoring the expression of the
GLT-1 in the spinal cord decreases neuropathic pain behavior
[78]. While one could argue that decreasing glutamate in the
ganglion might offset some of the inhibitory effect glutamate has
through its group II and III metabotropic receptors, recent
evidence suggest that at least the mGluR7 receptor is down-
regulated after injury, which contributes to increased nociception
[77]. Finally, the concept that peripheral glutamatergic transmis-
sion could be a significant contributor to changes in gene
expression in the sensory neurons is supported by the finding that
selective knockdown of the NMDA receptor in primary afferent
neurons prevents the sensitization of primary afferents [16].
Conclusion
This study provides evidence that all the components for
receptor mediated glutamatergic transmission are present in the
sensory ganglia and that glutamate expression increases in primary
sensory neurons following nerve injury. These finding further
support the idea that peripheral, and intraganglionic in particular,
glutamatergic transmission can be a factor in the initiation and/or
maintenance of pain following nerve injury.
Supporting Information
Figure S1 Immunocytochemistry of some proteins associated
with glutamate vesicle-packaging and release. Each row of images
(A–D) show the vesicle associated protein, SGCs labeled with
glutamine synthetase and the merged image. Some of these
proteins are found only in neurons (SNAP25, A), some only in
SGCs (Cellubrevin, C) and other occur in both cell types
(synaptobrevin, B and secretory carrier-associated membrane
protein 1 [SCAMP1], D). Scale bar: A, C, D= 10 mm, B=30 mm.
(TIF)
Figure S2 Immunocytochemistry of glutamate receptor expres-
sion in sensory ganglia. Some of the glutamate receptors are found
in both neurons and SGCs (NR2A, A; GluA4, C3; mGluR8, D3).
Subunit GluK2 of kainate receptors is found only in SGCs (B).
Double label of glutamine synthetase (GS) a marker for SGCs and
GluA4 or mGluR8 are shown from C1to C3 and D1 to D3
respectively. Arrows: SGCs, Arrow head: SGC nucleus. Scale bar:
A=30 mm, B= 25 mm, C, D=30 mm.
(TIF)
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